Skip to main content

Table 3 Plasma cohort: Demographic and clinical characteristics and soluble ADAM15 levels

From: ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction

Characteristics Non-smokersa (N = 28) Smokersa (N = 27) COPD GOLD stage I-II (N = 27) COPD GOLD stage III-IV (N = 33) P valuec
Number of males (%) 18 (64.3) 17 (63) 23 (85) 20 (60.6) NS
Age (years) 66 (35–77) 62 (50–74) 67 (53–83) 65 (48–82) NS
Pack-yrs. of smoking 0 50 (15–96) 60 (20–127) 68 (12–160) P ≤ 0.049d
Number of current smokers (%) 0 (0) 3 (10) 14 (52) 7 (21) P ≤ 0.03e
FEV1(% of predicted)b 98 (79–147) 91 (65–119) 65 (50–105) 35 (17–49) P < 0.001f
FEV1/FVC (% of predicted)b 77 (70–86) 76 (71–84) 57 (38–68) 39 (26–59) P < 0.001g
Plasma sADAM15 Levels (pg/ml) 665 (175–2457) 642 (256–2393) 517 (64–1110) 672 (54–3533) NSh
  1. The table shows the demographic and clinical characteristics of the patients with COPD, smokers without COPD, and non-smoker controls included in the analysis of plasma soluble ADAM15 protein levels. Patients with COPD were sub-divided according to the Global Initiative for Obstructive Lung Disease (GOLD) criteria
  2. Data are presented as median (interquartile range) for data that were not normally distributed or mean ± SD for data that were normally distributed
  3. a Non-smokers were all never-smokers. Smokers were defined as subjects that had > 10 pack-year smoking history. Current smokers were defined as active smokers at the time of the biopsy or surgery or had stopped smoking < 1 year before the sample was obtained
  4. b All patients with COPD had a forced expiratory volume in 1 s/forced vital capacity ratio (FEV1/FVC) < 0.7 whereas smokers without COPD and non-smoker controls had a FEV1/FCV ratio > 0.7
  5. c Categorical variables were analyzed with z-test. Statistical analyses included One-Way ANOVA tests for continuous variables (age, FEV1% predicted, FEV1/FCV, and pack/years) followed by pair-wise comparisons using 2 tailed Student’s t-tests for parametric data or Mann-Whitney U tests for non-parametric data
  6. d The pack/year smoking histories of the GOLD stage I-II and GOLD stage III-IV COPD groups and the smoker group were significantly different from those of the non-smoker group by design (P < 0.001 for both comparisons). The pack/year smoking histories of the GOLD stage III-IV COPD group were significantly different from those of the smoker group (P = 0.049), but not significantly different from those of the GOLD stage I-II COPD group (P = 0.48). The pack/year smoking histories of the GOLD stage I-II COPD group were not significantly different from that of the smoker group (P = 0.2)
  7. e The proportion of current smokers in the GOLD stage I-II COPD patients was significantly different from that of the non-smokers, smokers, and GOLD stage III-IV COPD patients (P < 0.001, P = 0.003, and P = 0.03, respectively). The proportion of current smokers in the GOLD stage III-IV COPD group was significantly different from that of the non-smoke group (P = 0.029), but not significantly different from that of the smoker group (P = 0.43)
  8. f The FEV1 values of the GOLD stage III-IV COPD patients were significantly different from those of the non-smoker, smoker, and GOLD stage I-II COPD groups (P < 0.001 for all comparisons). The FEV1 values of the GOLD stage I-II COPD group were significantly different from those of the smoker and non-smoker groups (P < 0.001 for both comparisons)
  9. g The FEV1/FVC ratios of the GOLD stage III-IV COPD group were significantly different from those of the non-smoker, smoker, and GOLD stage I-II COPD groups (P < 0.001 for both comparisons). The FEV1/FVC ratios of the GOLD stage I-II COPD patients were significantly different from those for the smoker and non-smoker groups (P < 0.001 for both comparisons)
  10. hSoluble ADAM15 levels in plasma samples (medians and interquartile ranges) are shown in the Table. P values were adjusted to correct for differences in pack-years of smoking history and current smoker status between the COPD patients and controls using an ordinal logistic regression model. After adjusting for these covariates, plasma sADAM15 levels were not significantly different between the COPD patients and controls
  11. NS not significant